United States Food and Drug Administration (USFDA) has concluded inspection at Torrent Pharmaceuticals’ Indrad, Gujarat manufacturing facility. The USFDA inspected facility from September 19, 2022 to September 28, 2022. At the end of the inspection, the company have been issued a ‘Form 483’ with 3 observations. None of these observations were related to data integrity.
Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.